J&J’s Strong Phase 1 Prostate Cancer Data Intensifies Competitive Pressure on Oric

Oric shares declined after Johnson & Johnson reported a 75% tumor response rate with JNJ-6143 in heavily pretreated advanced prostate cancer patients.